

**Table S1. In vitro and in vivo antitrypanosomal activities of cationic diamidines.<sup>a</sup>**

	In vitro activity				In vivo activity			
	<i>T. b. r.</i> STIB900wt		<i>T. b. b.</i> BS221		<i>T. b. r.</i> STIB900 acute		<i>T. b. b.</i> GVR35 CNS	
	IC <sub>50</sub> , ng/ml	IC <sub>50</sub> , μM	IC <sub>50</sub> , ng/ml	IC <sub>50</sub> , μM	4 x 20 mg/kg i.p.		10 x 20 mg/kg i.p.	
<b>Pentamidine</b>	1.2	0.0020	0.9	0.0015	2/4 <sup>b</sup>	50% <sup>c</sup>	0/4 <sup>d</sup>	0%
<b>DB75</b>	1.0	0.0027	1.2	0.0032	3/4	75%	1/4 <sup>e</sup>	25%
<b>DB820</b>	2.4	0.0052	2.8	0.0060	4/4	100%	1/5	20%
<b>DB829</b>	6.5	0.0147	6.0	0.0135	4/4	100%	4/4	100%

<sup>a</sup> Most values were derived from an earlier publication by Wenzler et al. (6).

<sup>b</sup> # of cures/# of mice treated.

<sup>c</sup> Percent cured.

<sup>d</sup> Pentamidine was evaluated at 10 x 12.5 and 10 x 25 mg/kg/day i.p.

<sup>e</sup> DB75 was evaluated at 10 x 12.5 mg/kg/day i.p. 10 x 25 mg/kg/day i.p. was toxic.